You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Cannabidiol for Treatment of Childhood Epilepsy–A Cross-Sectional Survey
|
|---|---|
| Published in |
Frontiers in Neurology, September 2018
|
| DOI | 10.3389/fneur.2018.00731 |
| Pubmed ID | |
| Authors |
Kerstin A. Klotz, Andreas Schulze-Bonhage, Victoria San Antonio-Arce, Julia Jacobs |
| Abstract |
Background: The interest in cannabidiol (CBD) for treatment of epilepsy has been increasing over the last years. However, practitioner's attitudes concerning the use of CBD for epilepsy treatment appears to be divided and data about its clinical use in daily practice are not available. Objective: To improve the knowledge about the current use of CBD amongst European practitioners treating children and adolescents for epilepsy. Methods: Cross-sectional survey using an open-access online questionnaire for physicians treating children or adolescents for epilepsy within eight European countries from December 2017 to March 2018. Results: One-hundred fifty-five physicians participated in the survey. CBD is increasingly used by 45% (69/155) of participants, treating a mean (range) number of 3 (1-35) with CBD. Only 48% of the participants prescribing CBD are exclusively using purified CBD to treat children and adolescents with epilepsy, the remainder also applies preparations containing delta9-tetrahydrocannabinol (THC). Reported daily CBD doses range from < 10 to 50 mg/kg body weight. Management of CBD therapy in regard of monitoring side effects and adjusting concomitant therapy differs widely amongst participants. Their primary objective for commencing CBD is improving patient's quality of life. Participants frequently receive inquiries about CBD treatment but only 40% may actively suggest CBD as a treatment option. Of the 85 participants currently not using CBD for epilepsy treatment, 70% would consider using CBD if available in their country of practice or given the opportunity to become familiar with this treatment option. Conclusions: CBD is increasingly used by participating physicians but individual experience remains limited. There are very diverse opinions about the use of CBD to treat epilepsy in children and adolescents and widely differing views on how to manage the CBD treatment. |
X Demographics
The data shown below were collected from the profiles of 60 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 18 | 30% |
| United States | 4 | 7% |
| South Africa | 1 | 2% |
| France | 1 | 2% |
| Netherlands | 1 | 2% |
| Thailand | 1 | 2% |
| Australia | 1 | 2% |
| Spain | 1 | 2% |
| Switzerland | 1 | 2% |
| Other | 0 | 0% |
| Unknown | 31 | 52% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 59 | 98% |
| Practitioners (doctors, other healthcare professionals) | 1 | 2% |
Mendeley readers
The data shown below were compiled from readership statistics for 86 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 86 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 15% |
| Student > Master | 12 | 14% |
| Student > Bachelor | 9 | 10% |
| Student > Doctoral Student | 7 | 8% |
| Student > Postgraduate | 7 | 8% |
| Other | 17 | 20% |
| Unknown | 21 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 21% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 9% |
| Neuroscience | 7 | 8% |
| Psychology | 7 | 8% |
| Biochemistry, Genetics and Molecular Biology | 6 | 7% |
| Other | 13 | 15% |
| Unknown | 27 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 46. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 June 2022.
All research outputs
#909,872
of 25,571,620 outputs
Outputs from Frontiers in Neurology
#299
of 14,726 outputs
Outputs of similar age
#19,172
of 346,541 outputs
Outputs of similar age from Frontiers in Neurology
#8
of 297 outputs
Altmetric has tracked 25,571,620 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 14,726 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.5. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 346,541 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 297 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.